PHILADELPHIA, March 29, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the fiscal year ended December 31, 2010. The net loss for the year (including non-cash effects) was approximately $13,136,000 or ($0.10) per share as compared to a net loss of $7,180,000 or ($0.07) per share in 2009. An adjustment and restatement at December 31, 2009 to record the change of fair value of the liability related to certain warrants issued in May 2009 resulted in a non-cash gain of $6,258,000 in 2009 as compared to a non-cash gain of $879,000 in 2010. This redeemable warrant liability will continue to be revalued to fair market each fiscal quarter and the resulting non-cash adjustment can have a significant impact on overall net profit or loss of the Company.
